Longeveron's cell therapy flops early walk test study as execs tout flimsy supporting data
Miami biotech Longeveron has sold itself to investors on the promise of using cell therapy to improve the lives of aging patients unable to walk for long distances, but new data don’t look promising at all.
Longeveron’s lomecel-B, a cell therapy for aging frailty, flopped the key six-minute walk test endpoint of a Phase 2b trial of the drug, the biotech said Friday, and investors weren’t pleased.
At 180 days, patients receiving the drug posted no significant improvement on a walk test compared to placebo, Longeveron said, “after adjusting for multiple comparisons using the Hochberg method” to determine false discovery. Lomecel-B is an off-the-shelf product using “medicinal signaling cells” derived from healthy donors’ bone marrow.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.